Blog Research
RETATRUTIDE PEPTIDE UK
Emerging Compound
Retatrutide Peptide UK: The Triple Agonist That Changed Weight Loss Research
Retatrutide is the first compound to simultaneously activate three metabolic hormone receptors: GLP-1, GIP, and glucagon. Developed by Eli Lilly, it has produced the largest weight reduction seen in any clinical obesity trial to date. With Phase 3 data now published and seven additional trials expected to complete in 2026, retatrutide represents the most significant development in metabolic peptide research since semaglutide. This guide covers what UK researchers need to know about the compound, its mechanism, the clinical data, and how it fits into the broader GLP-1 research landscape.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly and Company. It is a single molecule designed to activate three metabolic hormone receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
This triple agonist approach builds on the success of dual agonists like tirzepatide (Mounjaro/Zepbound), which activates GLP-1R and GIPR. By adding glucagon receptor activation, retatrutide engages an additional metabolic pathway that increases energy expenditure and hepatic lipid oxidation, effects that pure GLP-1 agonists do not produce.
Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) and is not yet approved by any regulatory agency. Lilly has projected potential approval in 2027, with analysts forecasting sales of over $15 billion by 2031.
Triple Agonist Mechanism: How Three Receptors Work Together
Each of retatrutide’s three receptor targets contributes a distinct metabolic effect:
| Receptor | Primary Effects | Also Activated By |
|---|---|---|
| GLP-1R | Appetite suppression, delayed gastric emptying, insulin secretion, glucose control | Semaglutide, tirzepatide, liraglutide |
| GIPR | Enhanced insulin sensitivity, improved lipid metabolism, reduced nausea vs GLP-1 alone | Tirzepatide |
| GCGR (glucagon) | Increased energy expenditure, hepatic lipid oxidation, fat mass reduction | Retatrutide only (among current clinical candidates) |
The glucagon component is the key differentiator. While glucagon has historically been associated with raising blood glucose, its metabolic effects at physiological doses include increased resting energy expenditure and enhanced hepatic fat oxidation. In the context of retatrutide, the concurrent GLP-1R activation counterbalances any glycaemic effect, resulting in net glucose control alongside the energy-expenditure benefits of glucagon signalling.
A 2025 review in Biomolecules described retatrutide as a groundbreaking advancement in obesity pharmacotherapy, noting its novel approach of targeting three pivotal receptors that regulate glucose homeostasis simultaneously through a single molecular entity.
Katsi V, et al. “Retatrutide: A Game Changer in Obesity Pharmacotherapy.” Biomolecules. 2025;15(6):796. PMC12190491
Clinical Trial Data
Phase 2 (published in The Lancet, 2023): In a 48-week trial of 338 adults with obesity, participants receiving the highest dose of retatrutide (12mg) achieved an average weight loss of 24.2% of body weight. This was the largest weight reduction reported in any Phase 2 obesity trial at the time of publication.
Phase 3 TRIUMPH-4 (December 2025): In the first Phase 3 readout, retatrutide met all primary and key secondary endpoints. Participants receiving the 12mg dose achieved an average weight loss of approximately 28.7% at 68 weeks, with significant improvements in pain and physical function in patients with knee osteoarthritis. This remains the largest weight reduction reported in any Phase 3 obesity trial.
Ongoing TRIUMPH program: Seven additional Phase 3 trials are expected to complete in 2026, evaluating retatrutide in type 2 diabetes, obstructive sleep apnoea, chronic low back pain, cardiovascular outcomes, renal outcomes, and metabolic liver disease. A maintenance dose of 4mg is also being evaluated alongside the 9mg and 12mg doses.
| Trial | Phase | Duration | Key Result |
|---|---|---|---|
| Rosenstock et al. 2023 | Phase 2 | 48 weeks | 24.2% weight loss (12mg) |
| TRIUMPH-4 (Dec 2025) | Phase 3 | 68 weeks | 28.7% weight loss (12mg) |
Retatrutide vs Semaglutide vs Tirzepatide
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Approval status | Approved (2021) | Approved (2023) | Phase 3 (est. 2027) |
| Peak weight loss | ~15-17% | ~20-22% | ~24-29% |
| Energy expenditure effect | Minimal | Minimal | Yes (glucagon component) |
The progression from single agonist (semaglutide) to dual agonist (tirzepatide) to triple agonist (retatrutide) represents a clear trajectory toward multi-receptor metabolic approaches. Each additional receptor activation has produced incrementally greater weight loss in clinical trials. For a broader look at GLP-1 research, see our Semaglutide Peptide Guide.
UK Availability and Legal Status
Retatrutide is not yet approved by the MHRA (or any other regulatory agency). It is an investigational compound currently in Phase 3 clinical trials. It cannot be prescribed by UK doctors and is not available through the NHS.
Research-grade retatrutide peptide is available from specialist peptide suppliers for laboratory investigation. As with all research peptides, it is sold strictly for research purposes and is not intended for human consumption. The legal framework is the same as for other research peptides: legal to purchase for research, illegal to market as a medicine. For the full legal picture, see our guide: Are Peptides Legal in the UK?
For related GLP-1 research compounds currently in stock, see our Weight Management category, including Acetyl GLP-1 + GIP 5mg and GLP-1 + GIP Pen 5mg.
Frequently Asked Questions
Where can I buy retatrutide peptide in the UK?
Research-grade retatrutide is available from specialist peptide suppliers for laboratory use. It is not available as a medicine, on prescription, or through the NHS. For related GLP-1 research compounds, browse our Weight Management category.
When will retatrutide be approved?
Eli Lilly has not announced a specific regulatory submission date. Industry analysts project potential FDA approval in 2027 based on TRIUMPH program timelines. MHRA approval in the UK would likely follow. Seven Phase 3 trials are expected to complete in 2026.
How much weight loss does retatrutide produce?
Phase 2 data showed 24.2% average body weight loss at 48 weeks. Phase 3 TRIUMPH-4 data showed approximately 28.7% at 68 weeks. These are the largest weight reductions reported in any obesity clinical trial to date. Individual results in clinical trials varied.
What is the difference between retatrutide and semaglutide?
Semaglutide (Ozempic/Wegovy) activates only the GLP-1 receptor. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The additional glucagon activation increases energy expenditure and hepatic fat oxidation. Clinical trial data shows retatrutide produces approximately 60-70% greater weight loss than semaglutide.
Browse GLP-1 Research Peptides
GLP-1/GIP agonists, metabolic peptides, and weight management compounds
Shop Weight Management →Research Use Only: Retatrutide is an investigational compound not approved for human use by any regulatory agency. All information in this article is based on published clinical trial data and is provided for educational and research reference purposes only. This does not constitute medical advice. All products sold by BioLab Peptides are for research and laboratory use only.
